Comparison of clinical outcome and pharmacoeconomics of high-dose intravenous iron(Iron Isomaltoside Injection) and oral iron in that treatment of iron deficiency anemia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072661

Enrollment

Unknown

Registered

2023-06-20

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia

Interventions

Intravenous iron group:Use of iron isomaltose on a simplified scale, intravenous infusion over 15 minutes

Oral iron group:Polysaccharide iron complex 0.3g was used once a day for 4 months after hemoglobin returned to normal.

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: DA patients admitted to the Department of Hematology from July 2022 to July 2025 were selected as the research objects. Inclusion criteria: Patients = 18 years old with IDA due to different causes SF<100ng/ml TSAT<20%

Exclusion criteria

Exclusion criteria: Women who are pregnant, nursing, or planning to become pregnant Severe hypersensitivity reactions to other parenteral iron agents are known Non-iron-deficiency anemia (e.g. hemolytic anemia) Decompensated cirrhosis or active hepatitis (alanine aminotransferase > 3 times the upper limit of normal) Patients with a history of allergy to more than 2 drugs

Design outcomes

Primary

Measure	Time frame
HB;	—

Secondary

Measure	Time frame
SF;TSAT;	—

Countries

china

Contacts

Public ContactLimin Liu

Hongci Hematology Branch of the First Affiliated Hospital of Soochow University

liminliu2006@163.com+86 152 6248 2466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026